Company intelligence / Profile preview

Hightide Ventures

Shenzhen, China

Ownership: Private
Employees: ~57
Development stage: Other

Overview

HTD1801 (berberine ursodeoxycholate) has met primary endpoints in clinical studies for T2DM, MASH, and PSC; received FDA Fast Track for MASH and PSC, and Orphan Drug for PSC; included in China's National Major New Drug Innovation Program.

Therapeutic areas: EndocrinologyNeurologyGastroenterologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Hightide Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hightide Ventures.

Explore the full profile